Anthony Letai, MD, PhD, was sworn in as the 18th National Cancer Institute (NCI) Director Sept. 29. Dr. Letai brings a distinguished background in oncology and cancer research, having served as professor of medicine at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute. His work has focused on cell death in cancer, the development of treatments and the identification of biomarkers. Letai will lead the largest funder of cancer research in the world, with a current budget of $7.2 billion.
As he begins his tenure, NCI has released its Fiscal Year (FY) 2027 Annual Plan and Professional Judgment Budget Proposal, requesting $11.5 billion for NCI in FY 2027. The proposal outlines the optimal level of investment needed to capitalize on emerging opportunities in cancer research. The FY 2027 request represents a $4.3 billion increase over NCI’s FY 2025 appropriation and approximately $7 billion more than the FY 2026 President’s budget request.
Key areas of proposed investment include:
ACR® has a longstanding relationship with NCI and remains committed to supporting ongoing and future advocacy efforts. For more information or if you have questions, contact Katie Grady, ACR Government Affairs Director.
ACR Backs Ultrasound Guidance for Trigger Point Care
ACR urges Medicare to cover ultrasound guidance for highârisk trigger point injections to improve safety and accuracy.
Read moreACR Supports Bill to Stabilize Medicare Physician Pay
ACR backs bipartisan H.R. 8163 which will stabilize Medicare physician pay by easing budget neutrality, fixing data errors, and capping annual cuts.
Read moreACR Flags Concern With White House FY 2027 Budget Request
ACR raises concerns about Trumpâs FY2027 budget, which cuts NIH by $6B, caps indirect costs, restructures institutes, and reduces ARPAâH funding.
Read more